INVION LIMITED — Capital/Financing Update 2011

Aug 2, 2011

==> picture [594 x 105] intentionally omitted <==

3 August 2011

The Manager Company Announcements Office ASX Limited 20 Bridge St SYDNEY NSW 2000

Dear Sir,

REPAYMENT OF SPRINGTREE CONVERTIBLE NOTE

CBio wishes to advise that pursuant to the terms and conditions of the Convertible Loan Agreement with the SpringTree Special Opportunities Fund, LP (“SpringTree”), it has repaid in cash the $150,000 convertible note issued to SpringTree which was due for repayment by 3 August 2011.

Details of the convertible notes on issue following this repayment are as follows:

Number	Class
2	Convertible Notes with a face value of $1,000,000 each expiring 31December 2011

For and on behalf of the Board of CBio Limited

BEN GRAHAM Company Secretary

About CBio Limited

CBio is an Australian ASX listed company established in 2000. CBio’s lead product XToll® is a potential newgeneration drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA). Global sales of RA therapies exceeded US$17 billion in 2008. Novo Nordisk A/S, a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into a licence agreement for the intellectual property rights relating to XToll®. XToll® has been trialled in over 330 patients with no pattern of treatment-emergent serious adverse effects. The company’s largest clinical trial to date completed in Q2 2011. CBio’s Board includes internationally experienced drug developers including Dr Goran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Thomas Lönngren (former Executive Director of the European Medicines Agency), Dr Terje

==> picture [594 x 105] intentionally omitted <==

Kalland (retired Vice President Biopharmaceuticals Research Unit- Novo Nordisk); Dr Peter Corr, Founder and coGeneral Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (formerly Director of the Baker Institute, 1990-2001).

About Rheumatoid Arthritis

Rheumatoid Arthritis is a chronic autoimmune disease, mainly characterised by inflammation of the lining of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. The effects of RA are systemic, which means it can affect other organs in the body, and cardiovascular dysfunction in addition to RA is common. RA symptoms can make even the simplest activities – such as opening a jar or taking a walk – difficult to manage. RA has a worldwide distribution with a prevalence of 1 to 2% – which currently equates to approximately 100 million people. Prevalence increases with age, approaching 5% in women over age 55. RA is two to three times more common in women than in men and generally occurs between the ages of 40 and 60, but it can also affect young children and older adults. Currently, there is no cure.

COMPANY & INVESTOR RELATIONS

Ben Graham Company Secretary CBio Limited T: +61 7 3841 4844 ben.graham@cbio.com.au

MEDIA LIAISON

Melanie Farris Manager, Corporate Projects CBio Limited T: +61 449 148 448 melanie.farris@cbio.com.au